Dr. Sonali M. Smith is the Elwood V. Jensen Professor of Medicine, Section Chief of Hematology/Oncology, Co-Leader of the Cancer Service Line, and Co-Director of the Lymphoma Program at the University of Chicago in the Department of Medicine. She is a clinical investigator in lymphoma and a clinical expert in Hodgkin and non-Hodgkin lymphomas. As faculty member at the University of Chicago since 2001, she has over 200 publications in peer-reviewed journals and has written over 25 review articles on lymphoid malignancies. She is particularly interested in targeted agents and pathway inhibitors, and has first and senior author publications through cooperative group trials and investigator-initiated trials. She has leadership roles including Vice-Chair of the SWOG Lymphoma Committee, immediate past-Chair of the Lymphoma Research Foundation Scientific Advisory Board, past-chair of the ASCO Communications Committee, past-Chair of the ASCO Annual Meeting Scientific Committee (2022), co-chair of the 2022 AACR Advances in Malignant Lymphoma, and co-chair of the ASH Meeting on Hematologic Malignancies. In 2025, she was elected to the ASCO Board of Directors for a 4-year term. She is one of the founding members and Steering Committee members of the international Women in Lymphoma (WiL) group. She has won numerous teaching awards and considers mentorship a key aspect of her career.
Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica. 2022 02 01; 107(2):353-354.
PMID: 34134474
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. Haematologica. 2022 01 01; 107(1):4-6.
PMID: 34985229
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
PMID: 28314699
New drugs for the treatment of non-Hodgkin lymphomas.
New drugs for the treatment of non-Hodgkin lymphomas. Chin Clin Oncol. 2015 Mar; 4(1):14.
PMID: 25841721
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul; 54(7):1405-10.
PMID: 23194022
Maintenance rituximab revisited: is it worth the cost?
Maintenance rituximab revisited: is it worth the cost? Leuk Lymphoma. 2012 Dec; 53(12):2331-2.
PMID: 22680766
Targeting mTOR in mantle cell lymphoma: current and future directions.
Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol. 2012 Jun; 25(2):175-83.
PMID: 22687453
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
PMID: 20837940
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct; 50(10):1606-17.
PMID: 19626540
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12.
PMID: 18640574